Strategy
Raising at a premium, for free.
Meet Dr Daniel Tillett. In late 2019, Dr Daniel Tillett, a biotech expert and investor, joined the board of Race Oncology. Despite expectations of a discount raise, he did something different: he invested at a premium. Since then, he’s raised $30m in a shareholder-driven round and never sold a